Barclays raised the firm’s price target on Insulet (PODD) to $286 from $274 and keeps an Underweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet: Strong Q4 Execution and Encouraging 2026 Outlook Offset by Valuation and Competitive Pressures, Justifying Hold Rating
- Insulet: Sustained Growth Runway and Underappreciated Long‑Term Upside Support Buy Rating
- Midday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
- Early notable gainers among liquid option names on February 18th
- Morning Movers: SolarEdge and Wingstop jump following quarterly results